Immunoassay for Neurological Biomarkers Market (2026 - 2033) Size, Share & Trends Analysis Report By Product (Instruments, Reagents, Services), By Disease (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis), By Application, By Region, And Segment Forecasts

Immunoassay For Neurological Biomarkers Market Summary

The global immunoassay for neurological biomarkers market size was estimated at USD 1.08 billion in 2025 and is projected to reach USD 2.12 billion by 2033, growing at a CAGR of 8.91% from 2026 to 2033. Growth is supported by the rising prevalence of neurodegenerative diseases, increasing demand for early diagnostics, wider adoption of minimally invasive blood-based testing, and advancements in high-sensitivity immunoassays.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Furthermore, the expanding use of neurological biomarkers in drug development and precision medicine. The growing demand for early diagnosis of neurological disorders is significantly supporting the immunoassay for neurological biomarkers market, as early-stage detection improves treatment outcomes and enables timely therapeutic intervention. Neurological diseases such as Alzheimer’s often remain undiagnosed in early stages, creating a strong need for accessible diagnostic tools. For instance, in October 2025, F. Hoffmann-La Roche received U.S. FDA clearance for its Elecsys pTau181 blood-based immunoassay, designed to aid in the early detection of Alzheimer’s disease in clinical and primary care settings. These tests help identify patients at earlier stages, improving referral efficiency, reducing diagnostic delays, and thereby increasing demand for immunoassay-based biomarker testing across healthcare systems.

To learn more about this report, Download Free Sample Report

The transition toward minimally invasive blood-based testing is accelerating the clinical adoption of immunoassays, as these methods offer improved patient compliance, reduced procedural risks, and greater scalability than cerebrospinal fluid (CSF) testing and imaging techniques. Blood-based immunoassays enable routine testing in primary care and laboratory settings, expanding access to neurological diagnostics. Technologies such as high-sensitivity digital immunoassays (e.g., Simoa platforms) enable the detection of low-abundance biomarkers, such as pTau217 and neurofilament light chain, with high diagnostic accuracy. For instance, in May 2025, Fujirebio received U.S. FDA clearance for its Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio test, a blood-based immunoassay designed to detect Alzheimer’s pathology. These advancements enhance analytical sensitivity, reproducibility, and throughput, supporting large-scale clinical deployment and broader market adoption.

The increasing integration of neurological biomarkers into drug development and precision medicine is supporting the growth of the immunoassays for neurological biomarkers industry, as biomarkers are critical for patient stratification, treatment monitoring, and clinical trial endpoint evaluation. The development of disease-modifying therapies for Alzheimer’s disease has intensified the need for accurate biomarker-based diagnostics to identify eligible patients at early stages. This growing reliance on biomarker-driven approaches is enhancing the clinical utility of immunoassays and reinforcing their role in advancing personalized treatment strategies and improving outcomes in neurological care.

Market Dynamics

Market Characteristics

The immunoassay for neurological biomarkers industry demonstrates a high degree of innovation, driven by advancements in ultra-sensitive detection technologies and automated platforms. The development of blood-based immunoassays for biomarkers such as phosphorylated tau, amyloid-beta, and neurofilament light chain has enabled early and minimally invasive diagnosis of neurological disorders. In addition, integration of high-throughput and multiplex immunoassay systems is improving diagnostic accuracy and laboratory efficiency. The growing use of biomarkers in drug development and precision medicine is further accelerating innovation, as companies continue to develop clinically validated assays that support patient stratification, disease monitoring, and large-scale adoption across healthcare systems, thereby strengthening the commercial potential of advanced immunoassay-based neurological diagnostics.

The market demonstrates a moderate to high level of M&A activity, driven by the need to expand technological capabilities and strengthen neurological biomarker portfolios. Companies are increasingly acquiring firms with expertise in ultra-sensitive and digital immunoassay technologies to enhance blood-based diagnostic solutions for neurodegenerative diseases. For instance, in July 2025, Quanterix Corporation completed the acquisition of Akoya Biosciences to establish an integrated platform for biomarker detection across blood and tissue samples. The acquisition strengthened Quanterix’s ultra-sensitive biomarker detection and digital immunoassay capabilities for neurology applications while expanding its multiplex biomarker analysis portfolio. Such strategic activities are accelerating innovation, commercialization, and competitive positioning within the immunoassays for neurological biomarkers market.

To learn more about this report, Download Free Sample Report

Regulations have a significant impact on the immunoassays for neurological biomarkers industry by ensuring test accuracy, safety, and clinical reliability. Regulatory approvals, particularly from agencies such as the U.S. Food and Drug Administration and European authorities under IVDR, govern the development and commercialization of diagnostic assays. While stringent requirements can delay product launches and increase costs, they also enhance standardization and build clinician confidence, thereby supporting wider adoption and long-term market growth.

Regional expansion in the immunoassay for neurological biomarkers industry is accelerating as companies expand their presence beyond established markets into high-growth regions. While North America and Europe continue to lead due to advanced healthcare infrastructure and early adoption of innovative diagnostics, companies are increasingly focusing on Asia-Pacific, Latin America, and the Middle East & Africa to capture emerging opportunities. Expansion strategies include strengthening distribution networks, forming local partnerships, and introducing cost-effective immunoassay solutions tailored to regional healthcare needs. In addition, growing awareness of neurological disorders, improved diagnostic infrastructure, and rising healthcare investments in developing economies are supporting broader adoption of immunoassay-based neurological diagnostics and driving overall market growth.

Product Insights

The reagents segment dominated the immunoassays for neurological biomarkers market, accounting for the largest share of 66.78% in 2025. Market growth increasing demand for ultra-sensitive immunoassay reagents for neurological disease detection. The market is transitioning from conventional reagents to advanced, high-sensitivity biomarker assay kits capable of detecting low-abundance neurological proteins associated with Alzheimer’s disease and other neurodegenerative disorders. For instance, in April 2026, Sysmex Corporation launched the HISCL p-Tau217 Assay Kit for Research Use in Europe, enabling automated measurement of blood-based p-Tau217 biomarkers associated with Alzheimer’s disease using its HISCL immunoassay systems. Such developments are accelerating the adoption of next-generation neurological biomarker reagents and supporting the expansion of immunoassay-based diagnostic applications across clinical and research settings.

The instruments segment is anticipated to witness significant growth over the forecast period, driven by the increasing adoption of automated, high-throughput immunoassay analyzers for neurological disease diagnostics. Growing commercialization of blood-based Alzheimer’s disease testing is further accelerating demand for advanced diagnostic instruments capable of ultra-sensitive biomarker detection. For instance, in January 2025, Beckman Coulter Diagnostics received U.S. FDA Breakthrough Device Designation for its Access p-Tau217/β-Amyloid 1-42 plasma ratio test developed for use on the DxI 9000 Immunoassay Analyzer. Such developments are strengthening the adoption of next-generation immunoassay instruments across clinical laboratories and neurological diagnostic settings.

Disease Insights

The Alzheimer’s disease segment held a 38.04% share of the immunoassays for neurological biomarkers industry in 2025, driven by the rising prevalence of Alzheimer’s disease and increasing demand for early diagnostic solutions. According to the Alzheimer's Association 2026 Alzheimer’s Disease Facts and Figures report, approximately 7.4 million Americans aged 65 years and older are living with clinical Alzheimer’s dementia in 2026, with prevalence increasing significantly among the aging population. Growing focus on early detection and biomarker-based diagnosis is accelerating the adoption of immunoassay testing for phosphorylated tau and amyloid-beta biomarkers. In addition, increasing government and research funding for neurodegenerative disease research is supporting the development of advanced neurological biomarker assays, thereby contributing to segment growth.

The Parkinson’s disease segment is anticipated to witness significant growth over the forecast period, driven by increased focus on biomarker-based diagnosis and precision medicine approaches for its management. Growing research efforts are accelerating the development of highly sensitive neurological biomarker assays for early disease detection and therapeutic monitoring. For instance, in March 2025, Quanterix Corporation announced expanded clinical research applications of its Simoa ultra-sensitive immunoassay platform for measuring alpha-synuclein and neurofilament light chain biomarkers associated with Parkinson’s disease and other neurodegenerative disorders. Such developments are strengthening biomarker-driven neurological research and supporting the adoption of advanced immunoassay technologies for Parkinson’s disease diagnostics and monitoring.

Application Insights

The research application segment captured the largest revenue share of 68.17% in 2025. Immunoassay plays a crucial role in neurological R&D; it is being used to determine pharmacokinetics of biologics and measure biomarkers & the levels of host cell proteins. Moreover, researchers are involved in identifying key biomarkers in serum and plasma to develop assays that are highly sensitive for determining the low levels of biomarkers. Merck’s Single Molecule Counting, an immunoassay kit, is one such example, highly sensitive for measuring neurological proteins in samples. All these factors are increasing the number of research organizations working on biomarker research & validation; pharmaceutical companies that are using biomarkers for drug discovery & development; and ambulatory surgery centers, thereby driving market growth.

To learn more about this report, Download Free Sample Report

The in vitro diagnostics application segment is anticipated to grow at a rapid CAGR of 14.6% over the forecast period, driven by increasing demand for biomarker-based testing for early diagnosis and therapeutic monitoring of neurological disorders. The growing availability of disease-modifying therapies for Alzheimer’s disease is accelerating the adoption of blood-based neurological biomarker diagnostics across healthcare systems. In addition, favorable reimbursement initiatives and increasing integration of neurological testing within clinical laboratory networks are supporting broader commercialization of in vitro diagnostic assays. The expanding use of minimally invasive immunoassay-based biomarker tests in primary care and specialty settings is further contributing to the market growth.

Regional Insights

North America dominated the global immunoassay for neurological biomarkers market, accounting for a share of 49.65% in 2025, driven by advanced healthcare infrastructure, high adoption of innovative diagnostic technologies, and strong research activity in neurodegenerative diseases. The region benefits from the presence of leading diagnostic companies and well-established laboratory networks, enabling rapid integration of immunoassay platforms. The increasing prevalence of Alzheimer’s disease and growing focus on early diagnosis and precision medicine are further supporting demand. In addition, favorable reimbursement frameworks and regulatory support are facilitating the adoption of blood-based biomarker testing, contributing to the sustained market growth.

To learn more about this report, Download Free Sample Report

U.S. Immunoassay for Neurological Biomarkers Market Trends

The U.S. immunoassay for neurological biomarkers industry accounted for a dominant share of North America in 2025, supported by a high burden of neurological diseases and strong clinical adoption of advanced diagnostics. The country has a robust ecosystem of diagnostic laboratories, research institutions, and pharmaceutical companies driving innovation in biomarker-based testing. Increasing emphasis on early disease detection, particularly for Alzheimer’s disease, is accelerating the adoption of minimally invasive immunoassays. Additionally, ongoing clinical trials and drug development activities are increasing demand for biomarker-driven diagnostics, while strong regulatory frameworks continue to support market expansion across the U.S.

Europe Immunoassay for Neurological Biomarkers Market Trends

Europe accounted for a considerable share of the global immunoassays for neurological biomarkers industry in 2025, supported by rising healthcare expenditure, an aging population, and increasing focus on early diagnosis of neurological disorders. The region is characterized by strong collaborations between academic institutions, healthcare providers, and diagnostic companies, driving innovation in biomarker testing. Regulatory advancements under frameworks such as the In Vitro Diagnostic Regulation (IVDR) are enhancing standardization and quality of diagnostic assays. Growing awareness of neurological diseases and expanding access to advanced diagnostics are further contributing to the market growth.

The immunoassay for neurological biomarkers market in the United Kingdom is driven by increasing investment in neurological research and strong government initiatives focused on early diagnosis of dementia and related disorders. The presence of leading academic institutions and integration of advanced diagnostic technologies within the National Health Service (NHS) are supporting the adoption of biomarker-based testing. The rising prevalence of Alzheimer’s disease and growing emphasis on precision medicine are further accelerating demand. Additionally, efforts to improve diagnostic pathways and patient outcomes are contributing to the market expansion.

The Germany immunoassays for neurological biomarkers market is supported by advanced healthcare infrastructure, strong diagnostic capabilities, and high adoption of innovative medical technologies. The country has a well-established network of clinical laboratories and research institutions actively engaged in neurological biomarker research. The increasing prevalence of neurodegenerative diseases and rising healthcare spending are driving demand for early and accurate diagnostic solutions. In addition, strong collaborations between academia, diagnostics companies, and pharmaceutical firms are supporting the development and commercialization of advanced immunoassays, contributing to the growth of the market in Germany.

Asia Pacific Immunoassay for Neurological Biomarkers Market Trends

Asia Pacific is expected to witness the fastest growth in the immunoassay for neurological biomarkers industry during the forecast period, driven by a rapidly aging population, increasing prevalence of neurological disorders, and improving healthcare infrastructure. Rising awareness regarding early diagnosis and expanding access to diagnostic services are supporting market expansion. Governments across the region are investing in healthcare modernization and research initiatives. In addition, the growing presence of global diagnostic companies and increasing adoption of automated laboratory systems are enhancing the availability of immunoassay-based testing, further accelerating the market growth.

The immunoassays for neurological biomarkers market in Japan is driven by a rapidly aging population and high prevalence of neurodegenerative diseases. The country has a strong focus on early diagnosis and disease management, particularly for Alzheimer’s disease and dementia. Advanced healthcare infrastructure and widespread adoption of innovative diagnostic technologies are supporting the integration of immunoassay-based biomarker testing into clinical practice. In addition, strong domestic diagnostic capabilities and ongoing research initiatives are contributing to the steady growth of the market.

The China immunoassay for neurological biomarkers market is experiencing rapid growth, driven by increasing healthcare investments and expanding diagnostic infrastructure. The rising burden of neurological disorders and growing awareness of early diagnosis are driving demand for biomarker-based testing. Government initiatives aimed at healthcare modernization and disease management are further supporting market expansion. In addition, the presence of both local and international diagnostic companies is accelerating the adoption of advanced immunoassay technologies, contributing to the growth of the market in China.

Latin America Immunoassay for Neurological Biomarkers Market Trends

The immunoassays for neurological biomarkers industry in Latin America is witnessing steady growth, driven by improving healthcare infrastructure and increasing awareness of neurological diseases. Countries such as Brazil and Mexico are experiencing rising demand for advanced diagnostic solutions. Efforts to expand healthcare access and investments in laboratory capabilities are supporting the adoption of immunoassay-based testing. However, cost constraints and limited access to specialized diagnostics remain challenges. Despite this, the growing focus on early diagnosis is contributing to the expansion of the regional market.

Middle East & Africa Immunoassay for Neurological Biomarkers Market Trends

The Middle East & Africa immunoassay for neurological biomarkers industry is at a developing stage, supported by increasing healthcare investments and rising awareness of neurological disorders. Countries in the Middle East are investing in advanced healthcare infrastructure, enabling the adoption of modern diagnostic technologies. In Africa, gradual improvements in healthcare access and public health initiatives are supporting market growth. However, limitations in diagnostic infrastructure and affordability challenges persist. Despite these factors, increasing focus on early disease detection is expected to support the market growth.

Key Immunoassay for Neurological Biomarkers Company Insights

The immunoassays for neurological biomarkers market is witnessing rapid growth, driven by strategic initiatives from key market participants to strengthen neurological biomarker testing capabilities and expand blood-based diagnostic solutions. Companies are focusing on collaborations, product innovation, regulatory approvals, and development of ultra-sensitive immunoassay platforms for neurodegenerative disease diagnostics. In addition, increasing investments in automated and high-throughput immunoassay systems are supporting early diagnosis, precision medicine, and biomarker-driven therapeutic research. Strategic partnerships between diagnostic companies, pharmaceutical firms, and research institutions are further accelerating the development and commercialization of advanced neurological biomarker assays, thereby contributing to the overall market growth.

Recent Developments

• In February 2026, Labcorp launched the FDA-cleared Elecsys pTau-181 blood test nationwide across primary care settings in the U.S. The test supports early assessment of Alzheimer’s disease through minimally invasive blood-based biomarker analysis and expands access to neurological biomarker testing beyond specialty care settings. The launch strengthened commercialization and clinical integration of immunoassay-based neurological diagnostics across healthcare systems.

• In October 2025, F. Hoffmann-La Roche Ltd. received U.S. FDA clearance for its Elecsys pTau181 plasma test developed in collaboration with Eli Lilly and Company. The blood-based immunoassay became the first FDA-cleared test for use in primary care settings to rule out Alzheimer’s-related amyloid pathology, supporting broader adoption of minimally invasive neurological biomarker diagnostics and improving accessibility of early Alzheimer’s disease assessment.

• In July 2025, Quanterix Corporation completed the acquisition of Akoya Biosciences to establish an integrated biomarker platform across blood and tissue diagnostics. The acquisition strengthened Quanterix’s ultra-sensitive digital immunoassay and multiplex biomarker analysis capabilities for neurology applications, supporting expansion of advanced neurological biomarker testing technologies and commercialization activities in the market.

Global Immunoassay for Neurological Biomarkers Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global immunoassays for neurological biomarkers market report based on product, disease, application, and region:

To learn more about this report, Download Free Sample Report

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Instruments

  • Reagents

  • Services

• Disease Outlook (Revenue, USD Million, 2021 - 2033)

  • Alzheimer's Disease

  • Parkinson's Disease

  • Multiple Sclerosis

  • Others

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • In Vitro Diagnostics Application

  • Research Application

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Delivered Customizations

This report has been delivered with the following In-depth customizations